Characterization of Antibody–Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM
Open Access
- 9 April 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 93 (15) , 6135-6144
Abstract
Antibody–drug conjugates (ADCs) pose challenges to bioanalysis because of their inherently intricate structures and potential for very complex catabolism. Common bioanalysis strategy is to measure the concentration of ADCs and Total Antibody (Ab) as well as deconjugated warhead in circulation. The ADCs and the Total Ab can be quantified with ligand binding assays (LBA) or with hybrid immunocapture–liquid chromatography coupled with multiple reaction monitoring mass spectrometry (LBA-LC-MRM). With the LBA-LC-MRM approach, a surrogate analyte, often the signature peptide, and released warhead can be used for the quantification of the Total Ab and ADCs, respectively. Recent advances in analytical instrumentation, especially the development of high resolution mass spectrometers (HRMS), have enabled characterization and quantification of intact macromolecules such as ADCs. The LBA-LC-HRMS approach employs immunocapture, followed by chromatographic separation at the macromolecule level and detection of the intact analyte. We developed an intact quantification method with 1–10 μg/mL linear dynamic range using 25 μL of plasma sample volume. This method was qualified for the measurement of naked monoclonal antibody (mAb), a site-specific cysteine-conjugated ADC with drug to antibody ratio ∼2 (DAR2) and a site-nonspecific cysteine-conjugated ADC (DAR8) in rat plasma. Samples from a rat pharmacokinetic (PK) study were analyzed with both methods. For the naked mAb, the results from both assays matched well. For ADCs, new species were observed from the LBA-HRMS method. The results demonstrated that potential biotransformation of the ADC was unveiled using the intact quantification approach while not being observed with traditional LBA-LC-MRM approach. Our work demonstrated an application of novel intact quantification by supporting animal PK studies. Moreover, our results suggest that the intact quantification method can provide novel perspectives on ADC in vivo characterization and quantification, which can benefit future drug candidate optimization as well as the immunogenicity impact evaluation and safety assessment.Keywords
This publication has 21 references indexed in Scilit:
- Calculated Conjugated Payload from Immunoassay and LC–MS Intact Protein Analysis Measurements of Antibody-Drug ConjugateBioanalysis, 2016
- A Whole-Molecule Immunocapture LC–MS Approach for The In Vivo Quantitation of BiotherapeuticsBioanalysis, 2016
- A Workflow for Absolute Quantitation of Large Therapeutic Proteins in Biological Samples at Intact Level Using LC-HRMSBioanalysis, 2016
- Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimidesJournal of Controlled Release, 2015
- LC–MS-Based Quantification of Intact Proteins: Perspective for Clinical and Bioanalytical ApplicationsBioanalysis, 2015
- Characterization of The Drug-To-Antibody Ratio Distribution for Antibody–Drug Conjugates in Plasma/SerumBioanalysis, 2013
- Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position PaperBioanalysis, 2013
- Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate BiotherapeuticsBioanalysis, 2013
- Strategy and Its Implications of Protein Bioanalysis Utilizing High-Resolution Mass Spectrometric Detection of Intact ProteinAnalytical Chemistry, 2011
- Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometryAnalytical Biochemistry, 2011